MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Genetics, Gene & Cell Therapy Companies
Tocagen (TOCA)
Organization & Developments: Tocagen
Parents
Tocagen (TOCA)
Children
2017: US Biotech/Pharma Sector Update: July 25: Featuring Tocagen, Targeting Malignant Glioma - Bhavneesh Sharma, MBA
2018: Reader Inquiry: Tocagen Is Looking Cheap But Is It A Buy? - Tocagen Inc (NASDAQ:TOCA)
2019: After Brain Cancer Drug Fails, Tocagen to Cut More Than Half of Staff
2019: Taking A Look At Tocagen_seekingalpha.com
2019: Tocagen fails brain cancer test, sets about 'operational review' as shares routed
2019: Tocagen: A Valuation - Tocagen Inc (NASDAQ:TOCA)
2019: Tocagen: Targeting High-Grade Glioma_seekingalpha.com
HGG has two forms: glioblastoma and astrocytoma.
Industry: Pharmaceuticals / Drugs Sub-Industry: N/A
The company is using retroviral replicating vectors to deliver therapeutics genes directly into cancer cells without any autoimmune toxicity.
Tocagen is a biopharmaceutical company pursuing the discovery, development and commercialization of products for the treatment of cancer.
ts primary focus is Toca 511 (vocimagene amiretrorepvec) and Toca FC to treat recurrent high-grade glioma, HGG.
Jumps
*Key People: Tocagen
Finance & Acquisitions: Tocagen